Bimal Kumar Das

Prof. Bimal Kumar Das


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
SSSanjeev Sinha
Sanjeev Sinha
AAAnuj Ajayababu
Anuj Ajayababu
HTHimanshu Thukral
Himanshu Thukral
SGSushil Gupta
Sushil Gupta
SGSubhasish Kamal Guha
Subhasish Kamal Guha
RPRavindra Mohan Pandey
Ravindra Mohan Pandey
Introduction Universal coverage of vaccines alone cannot be relied upon to protect at-risk populations in lower- and middle-income countries against the impact of the coronavirus disease 2019 (COVID-19) pandemic and newer variants. Live vaccines, including Bacillus Calmette–Guérin (BCG), are being studied for their effectiveness in reducing the incidence and severity of COVID-19 infection. Methods In this multi-centre quadruple-blind, parallel assignment randomised control trial, 495 high-risk group adults (aged 18–60 years) were randomised into BCG and placebo arms and followed up for 9 months from the date of vaccination. The primary outcome was the difference in the incidence of COVID-19 infection at the end of 9 months. Secondary outcomes included the difference in the incidence of severe COVID-19 infections, hospitalisation rates, intensive care unit stay, oxygen requirement and mortality at the end of 9 months. The primary analysis was done on an intention-to-treat basis, while safety analysis was done per protocol. Results There was no significant difference in the incidence rates of cartridge-based nucleic acid amplification test (CB-NAAT) positive COVID-19 infection [odds ratio (OR) 1.08, 95% confidence interval (CI) 0.54–2.14] in the two groups, but the BCG arm showed a statistically significant decrease in clinically diagnosed (symptomatic) probable COVID-19 infections (OR 0.38, 95% CI 0.20–0.72). Compared with the BCG arm, significantly more patients developed severe COVID-19 pneumonia (CB-NAAT positive) and required hospitalisation and oxygen in the placebo arm (six versus none; p = 0.03). One patient belonging to the placebo arm required intensive care unit (ICU) stay and died. BCG had a protective efficacy of 62% (95% CI 28–80%) for likely symptomatic COVID-19 infection. Conclusions BCG is protective in reducing the incidence of acute respiratory illness (probable symptomatic COVID-19 infection) and severity of the disease, including hospitalisation, in patients belonging to the high-risk group of COVID-19 infection, and the antibody response persists for quite a long time. A multi-centre study with a larger sample size will help to confirm the findings in this study. Clinical Trials Registry Clinical Trials Registry India (CTRI/2020/07/026668).

1 March 2005 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
SMSrujana Mohanty
Srujana Mohanty
BDBenu Dhawan
Benu Dhawan
AKArti Kapil
Arti Kapil
BDBimal Kumar Das
Bimal Kumar Das
PPParitosh Pandey
Paritosh Pandey
Aditya K GuptaAditya K Gupta
Aditya K Gupta

10 September 2020 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CRChandrabhan Rao
Chandrabhan Rao
BDBenu Dhawan
Benu Dhawan
SVSreenivas Vishnubhatla
Sreenivas Vishnubhatla
AKArti Kapil
Arti Kapil
BDBimal Kumar Das
Bimal Kumar Das
SSSeema Sood
Seema Sood

30 June 2018 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
PKPrathyusha Kokkayil
Prathyusha Kokkayil
RAReshu Agarwal
Reshu Agarwal
SMSarita Mohapatra
Sarita Mohapatra
SBSameer Bakhshi
Sameer Bakhshi
BDBimal Kumar Das
Bimal Kumar Das
AKArti Kapil
Arti Kapil
Introduction: Studies have shown a shift in the prevalence from Gram-positive to Gram-negative bacteraemia in patients with haematological malignancies who develop febrile neutropenia. There are also reports on the spread of drug resistant bacteria among these patients. Information about locally prevalent bacteria and their resistance is important to guide empirical therapy. The aim of this study was to characterise the bacterial spectrum and antibiotic resistance pattern of bacteraemia in neutropenic patients with haematological malignancies Methodology: In this retrospective study, patients admitted to Haematology and Oncology units over a period of 6 months with laboratory-confirmed positive blood cultures were enrolled. Information regarding demographic profile, clinical features, and microbiological profile were recorded. Standard procedures were applied to identify the isolates and their resistance patterns. The data collected was analysed statistically. Results:56 isolates from 53 patients were isolated of which majority were gram negative bacilli (GNB; n = 52 or 93%). Klebsiella pneumoniae (43%, n = 24) was the most frequently isolated bacteria followed by Enterobacter sp (20%, n = 11) and Escherichia coli (12%, n = 7). All isolates were susceptible to colistin. Susceptibility to cefaperazone-sulbactam, piperacillin-tazobactam and carbapenems were 32%, 28.6% and 26.8% respectively. The outcome was fatal for 25 patients. Conclusions: The study documented an alarming rise in the prevalence of GNB and their resistance. Though the results of the study may represent only the tip of the iceberg, the results demonstrate the need for treatment options for drug resistant isolates and for surveillance cultures.

13 January 2020 in International Reviews of Immunology
Verified
Journal Article
Closed access
NNNeema Negi
Neema Negi
BDBimal Kumar Das
Bimal Kumar Das
The discovery of an active lymphatic system in the meninges (dura mater) has opened up a wide range of possibilities for the role of CNS immunoglobulins in brain development in early fetal life or during infancy. The antibody-dependent and -independent functions of B cells in the immunopathogenesis of multiple sclerosis are not new to immunologists, yet their role in other neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease is incompletely understood. Deep cervical lymph nodes have emerged as a candidate site for autosensitization against CNS antigens and have been shown to provide the right kind of milieu for the dynamic interaction of antigen-presenting cells, B cells, and T cells. The presence of different B cells in the lymph nodes and the production of natural autoantibodies by B-1 cells have definitely unlocked another piece of the puzzle. At a time when CD19 and CD20 monoclonal antibodies have shown remarkable results in ameliorating the relapse and progression of multiple sclerosis, it is imperative to dissect out the diversity in B cell populations inside the CNS to identify new targets to improve current treatment regimens for neurodegenerative diseases. This review highlights the origin, migration, function, and regulation of B cells and the production of intrathecal immunoglobulins considering the previous and current findings and taking into account the differences between a healthy state and the changes that occur during an inflammatory or autoimmune response.

1 June 2019 in Clinical Immunology
Verified
Journal Article
Closed access
SMShesh Prakash Maurya
Shesh Prakash Maurya
BDBimal Kumar Das
Bimal Kumar Das
RSRavinder Singh
Ravinder Singh
STSonu Tyagi
Sonu Tyagi